Table 1. Characteristics of studies involved in mutation analysis of CTCs.
| First author (year of publication) |
1 Buim, M.E (2015) | 2 Fabbri, F (2013) | 3 Harb, W (2013) | 4 Raimondi, C (2014) | 5 Kalikaki, A (2014) | 6 Lyberopoulou, A (2015) | 7 Mostert, B (2013) | 8 Steinert G (2014) | 9 Mohamed Suhaimi, N.A (2015) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Total number of patients included | 26 | 40 | 15 | 40 | 31 | 52 | 43 | 28 | 40 | 315 |
| Patients’ gender (male/female) |
18/8 | 24/16 | 11/4 | 15/25 | 22/9 | 33/19 | 28/15 | 11/17 | 19/21 | 181/134 |
| Tumor location (colon/rectal) |
16 /10 | 29/11 | 12/3 | 28/12 | 31/0 | 41/11 | 26/17 | 23/5 | 22/18 | 228/87 |
| Number of patients with CTCs detected | 21 | 16 | 14 | 30 | 23 | 52 | 26 | 22 | 40 | 244 |
| Clinical stage | IV 21 | IV 16 | II 4 III 2 IV 8 |
IV 30 | IV 23 | II 6 III 24 IV 22 |
IV 26 | III 6 IV 16 |
I 8 II 14 III 15 IV 3 |
I 8 II 24 III 47 IV 165 |
| Time of blood sample draws | After chemotherapy and monoclonal therapy | Before treatment | After operation | After chemotherapy and monoclonal therapy | After chemotherapy and monoclonal therapy | Before treatment | Before tumor resection | Before or in the operation | After operation | |
| Cutoff number of CTCs | 2 cells | 5 cell | 5 cells | 1 cell | 1 cell | 2 cells | 3 cells | 2 cells | 1 cell | |
| Enrichment and antibody staining of CTCs | Isolation by size of epithelial tumors ( ISET) CD45- cells |
Density gradient centrifugation CK +/Hoechst +/ CD45- cells |
IsoFlux System EpCAM+ cell |
CellSearch EPCAM+/CK+/ DAPI +/CD45- cells |
CellSearch EPCAM+/CK+/ DAPI +/CD45- cells |
Density gradient centrifugation EpCAM+/ Vimentin+/CK+/CD45- cells |
CellSearch TM EPCAM+ |
CellSearch System EPCAM+/CK+ cells |
Size-based filtration unit CK+/DAPI+/ CD45- cell |
|
| Number of mutation in CTCs detected | KRAS: codons12 7/21 |
KRAS: codons12 3/16 |
KRAS: codons12 1/14 codons13 5/14 |
KRAS: codons12 6/30 |
KRAS: codons12 6/23 codons13 1/23 |
KRAS: codons12 29/52 codons13 0/52 BRAF: 4/52 |
KRAS: codons12 4/26 codons13 1/26 BRAF: 1/26 |
KRAS: codons12 4/22 codons13 2/22 BRAF: 1/19 |
KRAS: codons12 9/40 codons13 5/40 BRAF: 1/40 |
KRAS: codons12 69/244 codons13 14/244 BRAF: 7/137 |
| Number of mutation in tissue samples | KRAS: codons12 6/21 codons13 3/21 |
KRAS: codons12 6/16 codons13 3/16 |
KRAS: codons12 1/14 codons13 1/14 |
KRAS: codons12 13/30 |
KRAS: codons12 7/23 codons13 1/23 |
KRAS: codons12 26/52 codons13 0/52 BRAF: 6/52 |
KRAS: codons12 8/26 codons13 1/26 BRAF: 1/26 |
KRAS: codons12 8/22 codons13 1/22 BRAF: 3/19 |
KRAS: codons12 9/40 codons13 2/40 BRAF: 5/ 40 |
KRAS: codons12 84/244 codons13 12/244 BRAF: 15/137 |
| Number of mutations in both CTC and tissue samples | KRAS: 5 cases |
KRAS: 2 cases |
KRAS: 1 case |
KRAS: 2 cases |
KRAS: 5 cases |
KRAS: 26 cases BRAF: 4 cases |
KRAS: 4 cases BRAF: 1 case |
KRAS: 5 cases BRAF: 1 case |
KRAS: 9 cases BRAF: 1 case |
KRAS: 59 cases BRAF: 7 case |
| Subtype mutation of CTCs | KRAS codons12 codons13 | KRAS codons12 codons13 | KRAS codons12 codons13 | KRAS codons12 codons13 | KRAS codons12 codons13 | KRAS codons12 codons13 BRAF (V600E) |
KRAS codons12 codons13 BRAF (V600E) |
KRAS codons12 codons13 BRAF (V600E) |
KRAS codons12 codons13 BRAF (V600E) |
|
| Methods for mutative detection of CTCs | Pyrosequencing | Pyrosequencing | castPCR | RT-PCR | PNA-mediated PCR | RFLP assay and ASPCR | nested ASB PCR | aCGH PCR | HRM assay and ASPCR | |
| Tumor status (progression/stable) | 5/16 | NA | 7/6 | NA | 6/17 | NA | NA | NA | NA | 18/39 |
| NOS score | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 8.11 (mean) |
NA: not available; castPCR: Competitive Allele-Specific TaqMan PCR; PNA: peptide nucleic acid; RFLP: restriction fragment length polymorphism; nested ASB PCR: nested Allele-Specific Blocker PCR; aCGH PCR: array comparative genomic hybridization PCR; HRM: High resolution melt; ASPCR: Allele-specific PCR; NOS score: Newcastle–Ottawa Scale score.